Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. (Nasdaq: VIR) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information on its clinical programs, collaborations and financial position. This SEC filings page aggregates those documents and pairs them with AI-generated summaries to help readers understand the key points in each filing.
For Vir Biotechnology, important filings include Form 8-K current reports describing material events, such as the license agreement with Norgine Pharma UK Limited for commercial rights to the tobevibart and elebsiran combination in chronic hepatitis delta across Europe, Australia and New Zealand, and updates on clinical data from the SOLSTICE Phase 2 trial. Other 8-K filings reference quarterly financial results, including cash, cash equivalents and investments, research and development spending, and progress across the ECLIPSE registrational program and oncology pipeline.
Investors following Vir Biotechnology’s infectious disease and oncology strategy can use this page to locate quarterly and annual financial disclosures, business updates reported via 8-K, and other SEC documents that discuss collaborations, licensing arrangements and clinical milestones. AI-powered tools highlight key terms, summarize complex sections and make it easier to identify information related to chronic hepatitis delta development, PRO-XTEN dual-masked T-cell engagers, and the company’s use of platforms such as dAIsY and PRO-XTEN.
The page also provides access to filings that may include details on revenue categories such as collaboration, contract, grant and license revenue, as well as information about material agreements and clinical trial updates referenced in attached press releases. Real-time integration with EDGAR means new Vir Biotechnology filings appear here as they are made public, with concise AI explanations to support faster review and comparison over time.
Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini reported both equity awards and an automatic tax-related sale of company stock. He received a grant of 25,000 shares of common stock as restricted stock units under Vir’s equity incentive plan and a stock option for 50,000 shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the option will vest on February 22, 2027, with the remaining shares vesting in 36 equal monthly installments afterward. On February 23, 2026, 1,829 shares of common stock were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to satisfy tax withholding obligations tied to RSU vesting, and the filing states this sale was not a discretionary trade. After the tax-related sale, Sabatini directly owned 71,043 shares of Vir common stock, in addition to the newly granted 50,000 stock options.
Vir Biotechnology EVP & CFO Jason O'Byrne reported a mix of automatic tax-related sales and new equity awards. A total of 2,089 shares of common stock were sold on an open-market basis at $7.4528 per share under a Rule 10b5-1 arrangement solely to cover tax withholding on vesting restricted stock units, and the sale was not a discretionary trade.
On the prior day, O'Byrne received 55,000 shares of common stock as a restricted stock unit grant under the company’s equity incentive plan, bringing his common stock holdings to 166,338 shares at that time. He also received a stock option for 110,000 shares, with 25% vesting on February 22, 2027 and the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology EVP and Chief Medical Officer Mark Eisner reported a mix of stock grants and a small share sale. On February 22, 2026, he received 55,000 shares of common stock as a grant of restricted stock units and a stock option for 110,000 shares at an exercise price of $0.00. According to the terms, 25% of the option will vest on February 22, 2027, with the rest vesting in 36 equal monthly installments after that date. On February 23, 2026, 2,089 common shares were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to cover tax withholding on vesting RSUs, and this sale was described as automatic and mandatory rather than a discretionary trade. After these transactions, Eisner directly held 157,529 shares of common stock and the 110,000-share stock option.
Vir Biotechnology EVP and General Counsel Vanina de Verneuil reported a mix of stock sales and awards. On February 23, 2026, she completed an open-market sale of 4,445 shares of common stock at $7.4528 per share, described as an automatic, mandatory sale under a Rule 10b5-1 plan to cover tax withholding from vesting restricted stock units, rather than a discretionary trade. After this sale, she held 129,799 common shares directly.
On February 22, 2026, she acquired 55,000 shares of common stock through a grant of restricted stock units under the company’s equity incentive plan, and received a stock option for 110,000 shares. For the option, 25% of the shares will vest and become exercisable on February 22, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology, Inc. director and CEO Marianne De Backer reported both equity awards and a small share sale. On February 22, 2026, she received 570,000 stock options and 285,000 restricted stock units under the company’s equity plan, with options vesting 25% on February 22, 2027 and the rest in 36 monthly installments.
On February 23, 2026, 19,039 common shares were sold at $7.4528 per share in an automatic sale under a Rule 10b5-1 arrangement to cover tax withholding from RSU vesting, described as not a discretionary trade. After these transactions, she directly owned 1,035,466 common shares and indirectly held 53,118 shares via the Ureel-De Backer Family Trust.
VIR filed a Form 144 notice reporting proposed sales of common stock by an insider. The filing lists 1,616 common shares associated with restricted stock vesting on 02/23/2026 and records 2,089 common shares listed under securities sold during the past three months on 02/23/2026 by Mark D. Eisner.
The transactions are tied to compensation-related vesting and a broker-dealer record for Fidelity Brokerage Services LLC appears on 02/24/2026.
VIR notice of proposed sale: the filing shows 14,762 common shares listed as "Securities To Be Sold" on 02/23/2026 tied to restricted stock vesting and labeled "Issuer" for compensation.
The excerpt also records 19,039 common shares sold on 02/23/2026 by Marianne De Backer. Transaction counterparties and cash‑flow treatment are not stated in the provided excerpt.
VIR: Notice of proposed insider sale following restricted stock vesting. The filing reports 1,634 restricted common shares vested on 02/23/2026 as issuer compensation. It also discloses that Jason V. O'Byrne sold 2,089 common shares on 02/23/2026 for $15,568.90.
Brent Sabatini filed a Form 144 reporting a proposed sale of Common stock tied to a Restricted Stock Vesting event dated 02/23/2026 for 1430 shares. The excerpt also lists securities recorded as sold during the prior three months: 1530 on 02/13/2026 and 1829 on 02/23/2026.
Vanina A. Huard De Verneuil reported a Rule 144 notice to sell common stock tied to restricted stock vesting. The filing lists 3,117 shares to be sold on 02/23/2026 as part of a compensation vesting event and shows 4,445 shares sold during the past three months on 02/23/2026.